Gemcitabine Plus High-Dose 5-Fu/Leucovorin in the Treatment of Advanced or Metastatic Carcinoma of the Biliary Tract
Status:
Completed
Trial end date:
2012-08-01
Target enrollment:
Participant gender:
Summary
This is an open-label phase II trial with weekly gemcitabine plus high-dose 5-FU/leucovorin
infusion (HDFL) for patients with advanced or metastatic carcinoma of the biliary tract. The
primary endpoint is patients' response and the secondary endpoints are chemotherapy-related
toxicity, time to disease progression and overall survival. .
Phase:
Phase 2
Details
Lead Sponsor:
National Health Research Institutes, Taiwan
Collaborators:
Chang Gung Memorial Hospital Changhua Christian Hospital Chi Mei Medical Hospital China Medical University Hospital Mackay Memorial Hospital National Cheng-Kung University Hospital National Taiwan University Hospital Taipei Veterans General Hospital, Taiwan